ImmuCell Corp Files 8-K Report
Ticker: ICCC · Form: 8-K · Filed: Jan 16, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financial-update
Related Tickers: IMCL
TL;DR
IMCL filed an 8-K on Jan 16, 2025, likely with financial updates.
AI Summary
On January 16, 2025, ImmuCell Corporation filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that ImmuCell Corporation is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative or positive events, suggesting a routine disclosure.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
- 56 Evergreen Drive Portland, Maine 04103 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for ImmuCell Corporation?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events.
On what date was this 8-K report filed?
The report was filed on January 16, 2025.
What is ImmuCell Corporation's principal executive office address?
The principal executive office is located at 56 Evergreen Drive, Portland, Maine 04103.
What is the SEC file number for ImmuCell Corporation?
The SEC file number is 001-12934.
What is the Standard Industrial Classification (SIC) code for ImmuCell Corporation?
The SIC code is 2835, which corresponds to "IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES."
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-16 16:05:09
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq
Filing Documents
- ea0227944-8k_immucell.htm (8-K) — 29KB
- ea022794401ex99-1_immucell.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-25-004200.txt ( ) — 231KB
- iccc-20250116.xsd (EX-101.SCH) — 3KB
- iccc-20250116_lab.xml (EX-101.LAB) — 33KB
- iccc-20250116_pre.xml (EX-101.PRE) — 22KB
- ea0227944-8k_immucell_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events On January 16, 2025 ImmuCell Corporation (the "Company") issued a press release announcing the settlement of an insurance claim related to certain production contamination events. The information in Item 8.01 and Exhibit 99.1 to this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated January 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: January 16, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated January 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3